Buy Dextromethorphan (cough) Cas 125-71-3

Dextromethorphan is a cough suppressant used in many cough and cold medicines.^[6] In 2022, the US Food and Drug Administration (FDA) approved the combination dextromethorphan/bupropion to serve as a rapid-acting antidepressant in people with major depressive disorder.^[7]

It is in the morphinan class of medications with dissociative and stimulant properties (at lower doses). Dextromethorphan does not have a significant affinity for the mu-opioid receptor activity typical of morphinan compounds and exerts its therapeutic effects through several other receptors.^[8] In its pure form, dextromethorphan occurs as a white powder.^[9]

When exceeding approved dosages, dextromethorphan acts as a dissociative hallucinogen. It has multiple mechanisms of action, including actions as a nonselective Serotonin–norepinephrine reuptake inhibitor^[10] and a sigma-1 receptor agonist.^[11][12] Dextromethorphan and its major metabolite dextrorphan also block the NMDA receptor at high doses, producing effects similar to those of other dissociative anesthetics such as ketamine, nitrous oxide, and phencyclidine.

It was patented in 1949 and approved for medical use in 1953.^[13] In 2023, the combination with promethazine was the 252nd most commonly prescribed medication in the United States, with more than 1 million prescriptions;^[14][15] and the combination with brompheniramine and pseudoephedrine was the 281st most commonly prescribed medication in the United States, with more than 700,000 prescriptions.^[14][16]

The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and the common cold), or from inhaled particle irritants, as well as chronic cough at a higher dosage.^[17][18]

In December 2025, the combination medication naproxen/dextromethorphan/guaifenesin (brand name Mucinex 12HR Cold & Fever Multi-Symptom) was approved for medical use in the United States.^[19]

In 2010, the FDA approved the combination drug dextromethorphan/quinidine under the brand name Nuedexta^[20] for the treatment of pseudobulbar affect (uncontrollable laughing/crying). Dextromethorphan is the active therapeutic agent in the combination; quinidine merely serves to inhibit the enzymatic degradation of dextromethorphan and thereby increase its circulating concentrations via inhibition of CYP2D6.^[21]

The combination medicine dextromethorphan/bupropion is approved for major depressive disorder under the brand name Auvelity.^[22][23]

Side effects of dextromethorphan at normal therapeutic doses can include:^[5][18][24]

A rare side effect is respiratory depression.^[18]

Dextromethorphan was once thought to cause Olney’s lesions when administered intravenously; however, this was later proven inconclusive, due to lack of research on humans. Tests were performed on rats, giving them 50 mg or more every day for as long as a month. Neurotoxic changes, including vacuolation, have been observed in posterior cingulate and retrosplenial cortices of rats administered other NMDA receptor antagonists such as PCP, but not with dextromethorphan.^[25][26]